Ebolavirus glycoprotein (specific to Zaire ebolavirus glycoprotein and Sudan ebolavirus glycoprotein) (GP (sometimes specified as GP(ZEBOV) for Zaire or GP(SEBOV) for Sudan))

Ebolavirus glycoprotein (GP) is the sole transmembrane glycoprotein on the surface of ebolavirus particles, including Zaire and Sudan species[1][2][3][4]. It is synthesized as a single precursor and cleaved into two subunits, GP1 (responsible for receptor binding) and GP2 (mediates membrane fusion), which assemble as a hetero-hexameric trimer on the virion surface[1][3]. The GP is highly glycosylated and forms a glycan shield that helps viruses evade the immune response[4][6]. GP mediates viral entry by attaching to host cell receptors and catalyzing the fusion of viral and cellular membranes—a process that requires proteolytic cleavage by host cathepsins and interactions with cellular lectins[1][6]. As the principal target for neutralizing antibodies, GP is the key antigen for vaccines, monoclonal antibody therapeutics, and entry inhibitors[1][2][4]. Differences in the structure and glycosylation of Zaire and Sudan ebolavirus GPs underlie significant variation in immune recognition and therapeutic efficacy, necessitating careful distinction in both research and medical applications[6]. If you later need structured information separately for “Zaire ebolavirus glycoprotein” and “Sudan ebolavirus glycoprotein”, they should each be treated as distinct canonical targets, though their properties are otherwise largely parallel except for sequence, immunogenicity, and some structural differences.

Other names

Ebolavirus envelope glycoproteinEbola GPGP1,2ZEBOV GP (for Zaire)SEBOV GP (for Sudan)Ebola virus glycoproteinSurface glycoprotein (sometimes “S” in literature, but not recommended)“GP” (most common abbreviation in research)

Neutralizing antibodies: Bind GP to block viral attachment or fusion, neutralizing infectivity[1][2][4]. Small-molecule inhibitors: Block GP processing (e.g., cathepsin inhibition) or interfere with conformational changes[1]. Vaccines: Use GP to elicit protective immune response